Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Thymoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 33 Cholangiocarcinoma 11 Carcinoma, Renal Cell 7 Stomach Neoplasms 5 Neoplasms 4 Liver Neoplasms 4 Uterine Cervical Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Biliary Tract Neoplasms 3 Triple Negative Breast Neoplasms 2 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Kidney Neoplasms 2 Cirrhosis, Familial, with Pulmonary Hypertension 2 Breast Neoplasms 2 Advanced Solid Tumor 2 Vulvar Neoplasms 1 Urogenital Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumor, Adult 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Diseases 1 Neuroendocrine Tumors 1

Interventions

pembrolizumab 3 Radiotherapy 2 Drug Therapy 2 zimberelimab 1 lenvatinib 1 fludarabine 1 Sunitinib 1 Radiotherapy, Adjuvant 1 Proton Therapy 1 Paclitaxel 1 Immunotherapy 1 Heavy Ion Radiotherapy 1 Etoposide 1 Cyclophosphamide 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05832827 2023-10-23

Artemis

National Cancer Center, Japan

Phase 2 Recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡